|
|
La lettre / Jeudi 29 juin 2023
|
|
|
|
|
|
|
|
|
|
Friday 30 June at 11:30
Optical analysis of neuronal ionic currents in acute brain slices and its application to the study of channelopathies
|
Invited by Susanna Pietropaolo (INCIA)
|
|
|
|
|
|
|
|
Publication de l'équipe de Laurent Groc (IINS)
|
|
|
|
|
|
|
|
Ces deux équipes ont émergé de l'équipe NeuroCOG suite au décès de Joel Swendsen en 2022.
|
|
|
|
|
|
|
|
Pamstation en démo / Réservez votre journée du 19 septembre / Coup de projecteur sur Licor Clx
|
|
|
|
|
|
|
|
|
|
Optical analysis of neuronal ionic currents in acute brain slices and its application to the study of channelopathies
Invited by Susanna Pietropaolo (INCIA)
|
Lieu : Centre Broca
Invited my Valentin Nägerl (IINS)
|
|
Epigenetic mechanisms underlying the persistence of nicotine memories / How does the brain integrate sensory and emotional information?
|
Invited by Shauna Parkes (INCIA)
|
Rôle fonctionnel des Neurostéroïdes dans le cerveau: Identification du profil de régulation de la pregnénolone endogène sur le système endocannabinoïde et applications thérapeutiques
|
|
Dopamine as a teaching signal : VTA projections to the dorsal hippocampus trigger LTP and spatial learning.
|
|
Invited by Thomas Boraud (IMN)
|
|
|
|
|
|
Cajal lectures
June 30 – 9:00am
Stéphane Oliet (Neurocentre Magendie, Bordeaux University, France)
Astroglial contribution to NMDA receptor activity.
|
June 30 – 11:00am
Nathalie Rouach (Collège de France, France)
Astrocytes : the stars of brain plasticity.
|
July 1 – 9:00am
Bart Eggen (UMCG/RUG, The Netherlands)
Human microglia in development, health and disease.
|
July 3 – 9:00am
Sonia Garel (PSL University, France)
Microglia in early brain wiring: from circuit assembly to tissue integrity
|
July 3 – 11:00am
Eric Boué-Grabot (Bordeaux University, France)
Synaptic and microglial function of ATP P2X receptors in health and disease
|
July 3 – 5:30pm (Virtual talk)
Paola Arlotta (Harvard University, USA)
Changing neurons to shape glia: a tale of microglia and oligodendrocytes
|
July 6 – 9:00am
Soyong Hong (Dementia Research Institute, University College London, UK)
Microglia-synapse interactions: The triggers and the consequences.
|
July 6 – 2:30pm
David Belin (Cambridge Univeristy, UK)
Role of striatal astrocytes in the development of drug seeking habits
|
July 6 – 4:00pm
TDT Presentation
|
|
|
|
|
|
Pour tous
|
Avec Marc Auriacombe (Sanpsy) et Michel Lejoyeux (Hôpital Bichat)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
APPELS A PROJETS
|
New calls
|
|
|
|
Expire le 15 décembre 2023
|
|
Parmi les thèmes : liens entre santé humaine et environnement ; maladies neurodégénératives ; autisme et neuro-développement ; maladies psychiatriques ; douleur
|
|
Expire le 11 octobre 2023
|
|
« Les mécanismes sous-tendant les symptômes communs aux maladies du cerveau »
|
|
L’Inserm promeut les travaux destinés à caractériser les effets du changement climatique sur la santé et ses mécanismes sous-jacents.
|
|
Expire le 15 septembre 2023
|
|
Les projets peuvent relever de tous les domaines et disciplines participant à la lutte contre le cancer
|
|
Expire le 12 septembre 2023
|
|
Share your ideas and let 3Brain AG know how you would like to use their technology to advance neuroscience research.
|
|
support studies focused on improving the quality of ALS care or increasing the implementation of evidence-based care.
|
|
to support fundamental scientific research that advances understanding of the causes, treatments, and cures for human disease.
|
|
Recognising significant achievements by an individual in translational science
|
|
Expire le 19 juillet 2023
|
|
|
|
|
|
Ending soon
|
MSIF Du Pré Grants enable multiple sclerosis researchers and clinicians to undertake short placements in established MS research centres and clinics
|
|
funding to pursue a potentially ground-breaking, high-risk project for 2 years in basic research in ALS
|
|
less age-related disease.
|
|
Par le Centre d’Excellence sur les Maladies Neurodégénératives BIND
|
|
develop or adapt technologies that can help maintain or improve the health, independence, and/or quality of life of people living with ALS.
|
|
|
|
|
|
|
|
|
|
